The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Personalizing care in R/R follicular lymphoma: selecting patients for novel combination therapies
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses personalizing care in relapsed/refractory follicular lymphoma (R/R FL), particularly when selecting patients for novel chemotherapy-free bispecific triplet combinations. Dr Linton notes that fitness, age, and comorbidities must guide patient selection, and that these regimens should be reserved for higher-risk patients with early relapse. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s a number of factors that are important. There are patient factors such as fitness and the ability to tolerate that triplet combination because it is associated with a higher rate of infections and cytopenias and hypogammaglobulinemia. So you need to make sure that you’re selecting patients based on their age, fitness, comorbidity to tolerate that treatment...
There’s a number of factors that are important. There are patient factors such as fitness and the ability to tolerate that triplet combination because it is associated with a higher rate of infections and cytopenias and hypogammaglobulinemia. So you need to make sure that you’re selecting patients based on their age, fitness, comorbidity to tolerate that treatment. But I think it’s also important that you recognize that the person who’s relapsed early is the one who’s most likely to benefit. So it is a treatment that I would reserve for those higher-risk patients, whereas if you had a patient who progressed later, you might find that actually they would do very well with standard immunochemotherapy or less intensive therapy, which means that you could then reserve your bispecific antibodies or your triplet combination for later lines of therapy. When these patients have relapsed again, their risk is then higher and they’ve got fewer treatment options. So selecting the right patient at the right time is particularly important to avoid over-treating low-risk people.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
